Harrow, Inc. reported positive interim results from a prospective, randomized study of IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% in patients receiving same-day bilateral intravitreal injections. The update is supportive of the product’s clinical profile in this procedure setting, though no efficacy/safety magnitudes were disclosed in the provided text.
Harrow, Inc. reported positive interim results from a prospective, randomized study of IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% in patients receiving same-day bilateral intravitreal injections. The update is supportive of the product’s clinical profile in this procedure setting, though no efficacy/safety magnitudes were disclosed in the provided text.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
